Hemab ApS: Financial statements 2024
CVR: 40837590
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Hemab ApS (CVR 40837590) has filed annual accounts for 2024. Equity in the 2024 report amounted to USD 104,000. The company had 36 employees in the financial year.
- Equity
- USD 104,000
- Employees
- 36
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | - | - | 104 t. USD | 36 |
| 2023 | - | - | -22.8 mio. USD | 136.2 mio. USD | 21 |
| 2022 | - | - | -156.4 mio. | 6.1 mio. | 10 |
| 2021 | - | - | -35.2 mio. | 68 mio. | 3 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
Hemab ApS has published its annual report for 2023. The net result was DKK -22,783,000.
As of January 16, 2024, Akshay Krishnadas Vaishnaw has joined the board of directors of Hemab ApS.
About Hemab ApS
Hemab ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2019. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Ebumab Hemophilia ApS. The management consists of Benny Sørensen and Mads Nikolaj Behrndt-Eriksen. The board consists of John Michael Maraganore (chair), Akshay Krishnadas Vaishnaw, Benny Sørensen and Linda Catharina Bain. The company is owned by Hemab Therapeutics Holdings, Inc.. According to the 2025 annual report, the company had an average of 54 employees. Equity in the 2025 report amounted to USD 196,000.